Table 1.
Mitocan-based drug combinations ranked in order of decreasing combined synergy coefficient.
| Rank | Drug combination | Sum of maximal synergy coefficients in both cell lines | Maximal synergya, mean ± SEM, MOLM-13 | Maximal synergya, mean ± SEM, OCI-AML2 |
|---|---|---|---|---|
| 1. | ABT-199/VIN | 91.5 | 40.9 ± 9.1 | 50.5 ± 3.0 |
| 2. | RT/2-DG | 77.1 | 40.1 ± 5.7 | 36.9 ± 2.1 |
| 3. | ABT-199/DAS | 75.9 | 38.4 ± 0.5 | 37.6 ± 2.6 |
| 4. | CCCP/LND | 74.8 | 47.4 ± 9.4 | 27.4 ± 3.3 |
| 5. | ABT-199/3-BP | 69.5 | 28.0 ± 5.1 | 41.4 ± 5.7 |
| 6. | IACS-010759/VIN | 68.7 | 37.7 ± 5.6 | 31.0 ± 6.1 |
| 7. | RT/DAS | 63.9 | 38.6 ± 5.8 | 25.3 ± 0.9 |
| 8. | CCCP/DAS | 61.7 | 34.8 ± 5.7 | 26.8 ± 5.4 |
| 9. | RT/3-BP | 54.8 | 31.6 ± 3.7 | 23.2 ± 1.5 |
| 10. | IACS-010759/DAS | 51.0 | 32.1 ± 4.0 | 18.9 ± 5.0 |
| 11. | RT/LND | 49.1 | 21.5 ± 3.2 | 27.6 ± 8.8 |
| 12. | ABT-199/LND | 47.8 | 15.9 ± 7.2 | 31.9 ± 14.8 |
| 13. | ABT-199/2-DG | 44.8 | 25.6 ± 7.6 | 19.2 ± 3.9 |
| 14. | RT/VIN | 42.4 | 21.9 ± 7.6 | 20.6 ± 1.4 |
| 15. | ET/LND | 42.0 | 14.9 ± 3.5 | 27.1 ± 2.4 |
| 16. | RT/MID | 42.0 | 22.5 ± 3.3 | 19.5 ± 4.0 |
| 17. | ET/DAS | 41.6 | 22.1 ± 3.0 | 19.5 ± 3.3 |
| 18. | ET/MIDb | 39.5 | 6.7 ± 4.6 | 32.8 ± 3.9 |
| 19. | IACS-010759/MID | 38.1 | 26.8 ± 7.2 | 11.3 ± 2.4 |
| 20. | ara-C/MID | 38.0 | 13.1 ± 1.5 | 24.9 ± 1.6 |
| 21. | CCCP/2-DG | 37.3 | 23.5 ± 5.7 | 13.8 ± 2.7 |
| 22. | CCCP/3-BP | 34.6 | 23.6 ± 3.1 | 11.0 ± 0.7 |
| 23. | IACS-010759/2-DG | 32.9 | 19.9 ± 7.8 | 13.0 ± 3.1 |
| 24. | ET/VINb | 32.2 | 7.4 ± 4.0 | 24.7 ± 0.6 |
| 25. | ET/2-DG | 31.2 | 21.4 ± 2.2 | 9.8 ± 2.8 |
| 26. | ara-C/VINb | 30.3 | 5.7 ± 1.9 | 24.5 ± 2.0 |
| 27. | IACS-010759/LNDb | 29.0 | 23.1 ± 7.7 | 5.9 ± 2.3 |
| 28. | ara-C/3-BPb | 27.6 | 22.4 ± 1.5 | 5.1 ± 1.0 |
| 29. | ara-C/2-DG | 25.7 | 17.8 ± 3.9 | 7.9 ± 1.5 |
| 30. | ara-C/LND | 22.9 | 17.7 ± 6.9 | 5.1 ± 1.2 |
| 31. | ara-C/DAS | 19.3 | 8.6 ± 1.3 | 10.7 ± 0.4 |
| 32. | IACS-010759/3-BP | 19.0 | 8.8 ± 2.0 | 10.2 ± 3.2 |
| 33. | ET/3-BP | 12.4 | 7.4 ± 2.8 | 5.1 ± 3.3 |
| 34. | CCCP/VIN | 3.5 | 1.8 ± 1.8 | 1.7 ± 1.2 |
| 35. | ABT-199/MIDc | 2.1 | 2.1 ± 2.1 | 0 ± 0 |
| 36. | CCCP/MIDc | 0.0 | 0 ± 0 | 0 ± 0 |
a
Based on at least 3 independent biological replicates.
b
Drug combinations (n = 5) with opposite profile in MOLM-13 and OCI-AML2 cell line: maximal synergy higher than 20 in one cell line and lower than 10 in another one.
c
Drug combinations (n = 2), antagonistic in one or both AML cell lines.
Combinations (n = 22) fitting in the cutoff for testing on normal blood cells (average value of maximal synergy is equal to or higher than 20 in at least one cell line and equal to or higher than 10 in both cell lines) are in bold.